Search By:
Products
Injury
Topic
Company
Industry
Wyeths' Hormone Replacement drug PremPro may increase a woman's risk of breast cancer, stroke blood clots and heart attacks.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topic
- Increased Risk of Bodily Injury
Product or Service
- Prempro
Injury Types
- Blood Disorders and Clots
- Heart Attack
- Breast Cancer
- Stroke
Investigation Details
Investigation and numerous individual lawsuits against Wyeth for its continued, selling and distribution of PremPro.
PremPro is a form of Combined Hormone Replacement Therapy (CHRT), manufactured by Wyeth, prescribed to treat post-menopausal hot flashes and other menopause symptoms. PremPro differs from other forms of Hormone Replacement Therapy because it combines both estrogen and progesterone in a single tablet. PremPro consists of a single tablet containing 0.625 mg of the estrogens found in Premarin tablets and 2.5 mg or 5 mg of medroxyprogesterone acetate (MPA).
PremPro is manufactured by Wyeth and accounted for $890 million of the company's $13.9 billion in sales in 2001. Approximately six million women are taking PremPro. Recently, the nation's biggest hormone replacement study, conducted by the National Institute of Health (NIH), concluded that long-term use of PremPro is dangerous and outweighs its potential benefits because PremPro significantly increases the risk of stroke, blood clots, heart attacks and breast cancer. The risks were found to be so alarming that the NIH canceled the study in advance of the planned end date, citing risk to the study's participants.
Ever since Hormone Replacement Therapy was introduced, physicians and scientists were concerned about a potential increase in breast cancer. Women taking Prempro have a much higher risk of breast cancer, especially a rare form known as lobular breast cancer. A recent study showed that among women who used CHRT, like PremPro, there was a 210% increased risk of lobular breast cancer over women who had never used any type of HRT. This risk may be as high as 430%.
Do not change medications without first consulting your doctor.
PremPro is a form of Combined Hormone Replacement Therapy (CHRT), manufactured by Wyeth, prescribed to treat post-menopausal hot flashes and other menopause symptoms. PremPro differs from other forms of Hormone Replacement Therapy because it combines both estrogen and progesterone in a single tablet. PremPro consists of a single tablet containing 0.625 mg of the estrogens found in Premarin tablets and 2.5 mg or 5 mg of medroxyprogesterone acetate (MPA).
PremPro is manufactured by Wyeth and accounted for $890 million of the company's $13.9 billion in sales in 2001. Approximately six million women are taking PremPro. Recently, the nation's biggest hormone replacement study, conducted by the National Institute of Health (NIH), concluded that long-term use of PremPro is dangerous and outweighs its potential benefits because PremPro significantly increases the risk of stroke, blood clots, heart attacks and breast cancer. The risks were found to be so alarming that the NIH canceled the study in advance of the planned end date, citing risk to the study's participants.
Ever since Hormone Replacement Therapy was introduced, physicians and scientists were concerned about a potential increase in breast cancer. Women taking Prempro have a much higher risk of breast cancer, especially a rare form known as lobular breast cancer. A recent study showed that among women who used CHRT, like PremPro, there was a 210% increased risk of lobular breast cancer over women who had never used any type of HRT. This risk may be as high as 430%.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Wyeth (WYE) | Wyeth is a pharmaceutical company. It is now a subsidiary of Pfizer. |